PTO/SB/05e (12-08)
Approved for use through 01/31/2009 OMB 0651-0001
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION D	ISCLOSURE
STATEMENT BY	APPLICANT
(Not for submission un	der 37 CFR 1.99

	Application Number		10658873
	Filing Date		2003-09-05
	First Named Inventor	Micha	ael S. Kopreski
	Art Unit Examiner Name Lu,		1634
			rank Wei Min
	Attorney Docket Numb	er	00-1312-K

	U.S.PATENTS					Remove					
		Kind Code ¹	Issue Date Name of Patentee or Applicant of cited Document			Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear					
	1										
If you wisl	h to a	i dd additional U.S. Pate	nt citatio	n informa	ation pl	l lease click the	Add button.	_	Add		
			U.S.P	ATENT	APPLIC	CATION PUB	LICATIONS		Remove		
Examiner Cite Publication Number Kind Code			Kind Code ¹	Publication Name of Patentee or Applicant of cited Document			Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear				
	1										
If you wisl	h to a	dd additional U.S. Publ	ished Ap	plication	citation	n information p	olease click the Ad	d button	=		
				FOREIG	N PAT	ENT DOCUM	IENTS		Remove		_
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code4	Publication Date	Name of Patente Applicant of cited Document	e or	vhere Rel	or Relevant	т.
	1										Г
If you wis	h to a	dd additional Foreign P	atent Do	cument	citation	information pl	lease click the Add	button	Add		_
			NON	I-PATEN	IT LITE	RATURE DO	CUMENTS		Remove		
Examiner Initials*	Cite No	Include name of the a (book, magazine, jour publisher, city and/or	nal, seri	al, sympo	osium,	catalog, etc), o					Тв

	1	Vitetta et al. (1991), "Immunatioxins," In: Biologic Therapy of Cancer, (Ed. DeVita et al.) Lippincott Philadelphia pp. 482-495.	
	2	Wang et al. (1989), "Quantilation of mRNA by the polymerase chain reaction," Proc. Natl. Acad. Sci. U. S. A. 86: 9717-9721.	
	3	Wieczorek et al. (1987), Cancer Research 47: 6407-6412.	
	4	Wieczorek et al. (1989), Schweiz med Wischr 119: 1342-1343.	
	5	Wieczorek et al. (1985), Proc. Natl. Acad. Sci. U. S. A. 82: 3455-3459.	
	6	Wiedmann et al. (1994), PCR Methods Applic. 3: 551-564.	
	7	Yarruck et al. (1993), Cancer Research 52: 3257-3261.	
	8	Rohde et al. (2000), Clin. Cancer Res. 6: 4803-4809.	
	9	Keller et al. (1993), PCR Methods and Applications 3: 32-38.	
	10	Notice et al. (1994), J. Clin. Microbiology 32: 519-520.	
	11	Schmidt et al. (1995). J. Med. Virology 47: 153-160	П

12	Agiiullina et al. (1988), Eksp. Onkol (USSR) 10(4), English abstract.	
13	Schwarz et al. (1995), Res. Virol (Paris) 146(5), English abstract.	
14	Kato et al. (1993), Hepatology 19(1), abstract	
15	Glick et al. (1994), Molecular biotechnology. Principles and applications of recombinant DNA, ASM Press: Washington Dc. Table of Contents for Molecular Diagnostics (8) and Vaccines and Therapeutic Agents (9).	
16	Persing et al (1993), Diagnostic molecular microbology Principles and applications, Amer. Soc. Microbiol. Washington DC, Table of Contents for Principles of Diagnostic Molecular Microbiology and Viral Pathogens.	
17	Southall et al. (1990), Br. J. Cancer 61: 89-95.	
18	Kopreski et al. (2001), Ann. N. Y. Acad. Sci 945; 172-178.	
19	Yan-Sanders et al. (2002), Cancer Letters 183: 215-220.	
20	Khirmani et al. (2005), BioTechniques 38: 739-745.	
21	Schrader et al. (2002), BMC Cancer 2: 32.	
22	Fleischhacker et al. (2001), Ann. N. Y. Acad. Sci. 945: 179-188.	

	Application Number		10658873	
	Filing Date		2003-09-05	
INFORMATION DISCLOSURE	First Named Inventor Micha		hael S. Kopreski	
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit		1634	
(Not for Submission under or or it 1.50)	Examiner Name	Lu, Fr	rank Wei Min	
	Attorney Docket Numb	er	00-1312-K	

	23	Burd et al. (1989), Proc. Nafl. Acad. Sci. U. S. A. 86 9788-9792.	
	24	Burchill et al. (1995), Br. J. Cancer 71: 278-281.	
	25	Lasheeb et al. (1997), Genitourinary Medicine 73(4): 303-305.	
	26	Mermin et al. (1991), J. Infectious Diseases 164(4): 769-772.	
	27	Kopreski et al. (2001), Clin. Chem. 47: 362, abstract 9.	
	28	Perosi et al. (2006), Virchows Arch. 448: 7-15.	
	29	Tahara et al. (1999), Oncogene 18: 1561-1567.	
	30	Dasi et al. (2001), Lab. Investigation 81: 767-769.	
	31	Hasseimann et al. (2001), Oncol. Rep. 8: 115-118.	
	32	Ng et al. (2002), Clin. Chem. 48: 1212-1217.	
		0	

	Application Number		10658873	-	
	Filing Date		2003-09-05		
INFORMATION DISCLOSURE	First Named Inventor	Micha	ael S. Kopreski	_	
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit		1634		
(Not for Submission under 37 GFR 1.33)	Examiner Name	Lu, Frank Wei Min			
	Attorney Docket Number		00-1312-K		
			77	_	

34	Silva et al. (2001), Clin. Canoer Res. 7: 2821-2825.	
35	Silva et al. (2001), Oncol. Rep. 8: 693-696.	
36	Gal et al. (2001), Ann. N. Y. Acad. Sci. 945: 192-194.	
37	Durie et al. (2000), Acta Cnool. 39: 789-796.	
38	Miura et al. (2003), Oncology 64: 430-434.	
39	Wong et al. (2004), J. Clin. Pathol. 57: 766-769.	
40	Ma et al. (2007), Haematologica 92: 170-175.	
41	Arcari et al. (1984), Nucleic Acids Res. 12: 9179-9199.	
42	Rykova et al. (2006), Ann. N. Y. Acad. Sci. 1075; 328-333.	
43	Hernandez et al. (1999), Leukemia 13: 2087-2093.	
44	Zhou et al. (1998), Clin. Cancer Res. 4: 1631-1640.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10658873
iling Date		2003-09-05
irst Named Inventor Michael		ael S. Kopreski
Art Unit		1634
Examiner Name Lu, Fra		rank Wei Min
Attorney Docket Numb	er.	00-1312-K

Date Considered

			_
	45	Zhou et al. (2001), Breast Cancer Research and Treatment 66: 217-224.	
	46	Press et al. (1990), Oncogene 5: 953-962.	
	47	Ng et al. (2003), Proc. Natl. Acad. Sci. U. S. A. 100: 4748-4753.	
	48	Bairey et al. (2002), Arch. Pathol. Lab. Med. 126: 574-576.	
	49	Gilmour et al. (2001), Canoer Res. 61: 2169-2716.	
	50	Reinhold et al. (2001), Clin. Chem. 47: 369, abstract 50.	
If you wis	h to a	d additional non-patent literature document citation information please click the Add button Add	
		FYAMINER SIGNATURE	

See Kind Codes of USPTO Patent Documents at were USPTO.GDV or MPEP 901.04. * Entire office that issued the document, by the two letter code (WIPO Standard STS). * For Japanese patent documents, the selection of the year of the right of the Emperor stand precise the serial number of the patent document. Expenditure to the selection of the Comment of the Patent Standard STS in Expenditure 1. * Applicate the STS in Expenditur

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Signature